Skip to main content
Equibles
AIM logo

AIM · AIM ImmunoTech Inc. · Metrics

Track AIM — free

Use AIM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AIM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.21 0.00 (-2.10%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 7, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has incurred losses from operations and operating cash outflows exceeded cash inflows from operating activities for the six months ended June 30, 2026. These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”
View the 10-Q filed Aug 7, 2026
Market Cap
$6.50M
Shares
30.44M

AIM metrics

58 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.21
Market cap
$6.50M

Price action

20 metrics
Price change (1W)
-4.5%
Price change (30D)
-17.3%
Price change (3M)
-44.7%
Price change (6M)
-78.1%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
254.2%
Annualized volatility (3M)
78.2%
Beta
-0.3
RSI (14D)
37.8
Price vs SMA 50
-14.8%
Price vs SMA 200
—
Avg volume (3M)
4.74M
Relative volume
0.4
Average dollar volume
$1.13M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
30.44M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
39.8×
reciprocal yield 2.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
68.4×
reciprocal yield 1.5%
P / book
0.8
reciprocal yield 119.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-219.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
51.3×
reciprocal yield 1.9%
EV / revenue historical average (5Y)
66.1×
reciprocal yield 1.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-06-04

Profitability

9 metrics
Gross margin
—
Operating margin
-11,724.2%
Trailing 12 months
Net margin
-15,021.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$11.14M
Net income (TTM)
−$14.27M
Trailing 12 months
Diluted EPS (TTM)
$-6.01
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-3.09

Growth

11 metrics
Revenue growth YoY
+4.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$95,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2,154.6%
Year over year · more shares
Revenue CAGR (3Y)
-14.5%
Revenue CAGR (5Y)
-11.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-184.3%
Return on assets
-112.1%
Debt / equity
0.9
Current ratio
2.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.1
Interest coverage
-9.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$2.72M
Latest balance sheet
Cash & equivalents
$9.90M
Total assets
$12.73M
Total debt
$7.24M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$14.37M
Capital expenditures (TTM)
—
R&D (TTM)
$2.74M
SG&A (TTM)
—
Stock compensation (TTM)
$60,000
R&D / revenue
2,885.3%
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
19
13F filer change QoQ
+1
Institutional ownership
3.8%

Short interest

3 metrics
Short interest
1.9%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
41 / 100

Insider activity

2 metrics
Net insider buying (90D)
$13,456
Insider-sentiment score
80 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 946644 CUSIP 00901B303 Visit website Investor relations